micro-community-banner
  • Saved

1yr
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+) - PubMed

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+) - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39227284/

ADAPT-SC (NCT04735432) was designed to evaluate noninferiority of subcutaneous (SC) efgartigimod PH20 to intravenous (IV) efgartigimod in participants with generalized myasthenia gravis (gMG). ADAPT-SC+ (NCT04818671) is an open-label extension study...

The ADAPT-SC and ADAPT-SC+ studies confirm that subcutaneous efgartigimod PH20 is noninferior to intravenous efgartigimod, demonstrating long-term safety and efficacy in treating generalized myasthenia gravis.

  • Saved

1yr
Key Research Highlights in Neuromuscular Medicine from the 2024 AANEM Annual Conference

In this video recap of the 2024 AANEM Annual Conference, Dr. Dianna Quan, MD, AANEM President and faculty at the University of Colorado School of Medicine, along with Dr. Donald Sanders, MD, neuromuscular neurologist, and Dr. Massey, MD, neuromuscular specialist from Duke University School of Medicine, discuss pivotal research findings. Key highlights include promising advances in plasma exosomes as biomarkers for diabetic peripheral neuropathy and the application of artificial intelligence in ultrasound imaging to differentiate between neurogenic and myogenic changes. They also review a study comparing the effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis, emphasizing the role of immunosuppressive therapies in treatment planning. Overall, the conference underscored the importance of integrating innovative research and technology to enhance diagnostic and treatment approaches in neuromuscular medicine.

  • Saved

1yr
Key Research Highlights in Neuromuscular Medicine from the 2024 AANEM Annual Conference

In this video recap of the 2024 AANEM Annual Conference, Dr. Dianna Quan, MD, AANEM President and faculty at the University of Colorado School of Medicine, along with Dr. Donald Sanders, MD, neuromuscular neurologist, and Dr. Massey, MD, neuromuscular specialist from Duke University School of Medicine, discuss pivotal research findings. Key highlights include promising advances in plasma exosomes as biomarkers for diabetic peripheral neuropathy and the application of artificial intelligence in ultrasound imaging to differentiate between neurogenic and myogenic changes. They also review a study comparing the effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis, emphasizing the role of immunosuppressive therapies in treatment planning. Overall, the conference underscored the importance of integrating innovative research and technology to enhance diagnostic and treatment approaches in neuromuscular medicine.

  • Saved

1yr
Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment - PubMed

Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38321574/

Successful treatment of MG rests on timely combination of different interventions. Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long-term specialized follow-up is needed. Most patients...

Generalized myasthenia gravis treatment involves symptomatic drugs, thymectomy, immunosuppressants, and novel therapies like complement inhibitors. Regular follow-up, physical training, and tailored support are essential for improved outcomes. Cost limits access.

  • Saved

1yr
Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis - PubMed

Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38022544/

https://inplasy.com/?s=202370112, identifier 202370112.

Rozanolixzumab and batoclimab are the most effective monoclonal antibodies for generalized myasthenia gravis, but rozanolixzumab has higher adverse events. Further direct comparisons are needed to confirm these findings.